

Central Line Insertion Practices Adherence Monitoring

Page 1 of 2 *required for saving		
Facility ID:	Event #:	
*Patient ID:	Social Security #:	
Secondary ID:	Medicare #:	
	Middle:	
*Gender: 🗆 F 🛛 M 🗌 Other	*Date of Birth: / / (mm/dd/yyyy)	
*Sex at Birth: \Box F \Box M \Box Unknown	*Gender Identity (specify):	
	Male	
	Female Male-to-female transgender	
	Female-to-male transgender	
	Identifies as non-conforming	
	Other	
	Asked but unknown	
	*Date of Insertion: / / (mm/dd/yyyy)	
*Person recording insertion practice data:		
Central line inserter ID: Name, Last:	First:	
*Occupation of inserter:		
	t Other student Other medical staff	
	ician 🗌 Intern/resident 🗌 Registered nurse	
Advanced practice nurse Other (specify):		
*Was inserter a member of PICC/IV Team? Y		
*Reason for insertion:		
New indication for central line (e.g., hemodynamic monitoring, fluid/medication administration, etc.)		
Replace malfunctioning central line		
□ Suspected central line-associated infection		
Other (specify):		
If Suspected central line-associated infection, was the central line exchanged over a guidewire? \Box Y \Box N		
*Inserter performed hand hygiene prior to central line insertion: $\Box Y \Box N$ (if not observed directly, ask inserter)		
*Were all 5 maximal sterile barriers used? $\Box Y \Box N$		
*Maximal sterile barriers used: Mask \Box Y \Box N	Sterile gown 🗆 Y 🛛 N	
Large sterile drape \Box Y \Box N Sterile gloves \Box Y \Box N Cap \Box Y \Box N		
*Skin preparation (check all that apply) 🗌 Chlorhexidine	e gluconate \Box Povidone iodine \Box Alcohol	
□ Other (specif	y):	
If skin prep choice was <u>not</u> chlorhexidine, was there a contraindication to chlorhexidine? \Box Y \Box N \Box U		
If there was a contraindication to chlorhexidine, indicate the type of contraindication:		
Patient is less than 2 months of age - chlorhexidine is to be used with caution in patients less than 2 months of age		
□ Patient has a documented/known allergy/reaction to CHG based products that would preclude its use		
\Box Facility restrictions or safety concerns for CHG use in premature infants precludes its use		
*Was skin prep agent completely dry at time of first skin puncture? 🗌 Y 🗌 N (if not observed directly, ask inserter)		
*Insertion site: 🗌 Femoral 🗌 Jugular 🗌 Lower extremity 🗌 Scalp 🗌 Subclavian 🗌 Umbilical 🗌 Upper extremity		
Antimicrobial coated catheter used: \Box Y \Box N		
	veillance system that would permit identification of any individual or institution is collected s stated, and will not otherwise be disclosed or released without the consent of the individual,	



Page 1 of 2

or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

Public reporting burden of this collection of information is estimated to average 26 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS H21-8, Atlanta, GA 30333, ATTN: PRA (0920-0666). CDC 57.125 (Front)



Central Line Insertion Practices Adherence Monitoring

Page 2 of 2	.
*Central line catheter type:	
\Box Non-tunneled (other than dialysis)	
\Box Tunneled (other than dialysis)	Umbilical
Dialysis non-tunneled	□ Other (specify):
□ Dialysis tunneled	("Other" should not specify brand names or number of lumens; most lines can be categorized accurately by selecting from options provided.)
*Did this insertion attempt result in a successful central line placement? \Box Y \Box N	
Custom Fields	
Label	Label
///////	//
Comments	